Application of artificial intelligence in the diagnosis of urological tumors

doi:10.3969/j.issn.1006-7795.2026.02.002

Abstract

Abstract: Early diagnosis of urologic neoplasms is pivotal for delivering precision therapy and optimizing patient outcomes. In recent years, artificial intelligence (AI) has demonstrated remarkable potential in medical-image analysis, histopathologic image recognition, biomarker discovery, and prognostic prediction. This article systematically reviews the current status and advances of AI applications in the diagnosis of the three most common urologic cancers, including prostate cancer, bladder cancer, and renal cell cancer. By enhancing diagnostic efficiency, alleviating physicians' workload, and optimizing clinical decision-making, AI offers broad prospects. With continuous algorithmic refinement and the accumulation of multicentric data, AI is expected to play an even greater role in the precision management of urologic tumors.

Key words: artificial intelligence, urologic neoplasms, prostate cancer, bladder cancer, renal cell cancer, diagnosis

CLC Number:

R737

Shang Yaxin, Zhao Youquan, Xiong Tianyu, Niu Yinong, Xie Ping. Application of artificial intelligence in the diagnosis of urological tumors[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2026.02.002.

References

［1］Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2024, 74(3): 229-263.
［2］Haue A D, Hjaltelin J X, Holm P C, et al. Artificial intelligence-aided data mining of medical records for cancer detection and screening［J］. Lancet Oncol, 2024, 25(12): e694－e703.
［3］McSweeney S T, Werneburg G T, Vasavada S P. Artificial intelligence in the business of urology［J］. Urology, 2025, 203: 83-85.
［4］Hung A L Y, Zheng H X, Miao Q, et al. CAT-Net: a cross-slice attention transformer model for prostate zonal segmentation in MRI［J］. IEEE Trans Med Imaging, 2023, 42(1): 291-303.
［5］Wang X Y, Zhao J H, Marostica E, et al. A pathology foundation model for cancer diagnosis and prognosis prediction［J］. Nature, 2024, 634(8035): 970-978.
［6］Lee Y J, Moon H W, Choi M H, et al. MRI-based deep learning algorithm for assisting clinically significant prostate cancer detection: a bicenter prospective study［J］. Radiology, 2025, 314(3): e232788.
［7］Twilt J J, Saha A, Bosma J S, et al. AI-assisted vs unassisted identification of prostate cancer in magnetic resonance images［J］. JAMA Netw Open, 2025, 8(6): e2515672.
［8］Lorusso V, Kabre B, Pignot G, et al. External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection［J］. World J Urol, 2023, 41(3): 619-625.
［9］Duan J W, Bernard M, Downes L, et al. Evaluating the clinical acceptability of deep learning contours of prostate and organs-at-risk in an automated prostate treatment planning process［J］. Med Phys, 2022, 49(4): 2570-2581.
［10］Lindgren Belal S, Frantz S, Minarik D, et al. Applications of artificial intelligence in PSMA PET/CT for prostate cancer imaging［J］. Semin Nucl Med, 2024, 54(1): 141-149.
［11］Trägårdh E, Enqvist O, Ulén J, et al. Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians［J］. Eur J Nucl Med Mol Imaging, 2022, 49(10): 3412-3418.
［12］Ström P, Kartasalo K, Olsson H, et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study［J］. Lancet Oncol, 2020, 21(2): 222-232.
［13］Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer［J］. Cell, 2015, 163(4): 1011-1025.
［14］You S Y, Knudsen B S, Erho N, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome［J］. Cancer Res, 2016, 76(17): 4948-4958.
［15］Javadi G, Samadi S, Bayat S, et al. Multiple instance learning combined with label invariant synthetic data for guiding systematic prostate biopsy: a feasibility study［J］. Int J Comput Assist Radiol Surg, 2020, 15(6): 1023-1031.
［16］Chiu P K F, Shen X, Wang G J, et al. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study［J］. Prostate Cancer Prostatic Dis, 2022, 25(4): 672-676.
［17］Gontero P, Birtle A, Capoun O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—a summary of the 2024 guidelines update［J］. Eur Urol, 2024, 86(6): 531-549.
［18］Wu S X, Chen X, Pan J X, et al. An artificial intelligence system for the detection of bladder cancer via cystoscopy: a multicenter diagnostic study［J］. J Natl Cancer Inst, 2022, 114(2): 220-227.
［19］Shkolyar E, Jia X, Chang T C, et al. Augmented bladder tumor detection using deep learning［J］. Eur Urol, 2019, 76(6): 714-718.
［20］Wu P, Wu K, Li Z, et al. Multimodal investigation of bladder cancer data based on computed tomography, whole slide imaging, and transcriptomics［J］. Quant Imaging Med Surg, 2023, 13(2): 1023-1035.
［21］Wu S X, Hong G B, Xu A B, et al. Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study［J］. Lancet Oncol, 2023, 24(4): 360-370.
［22］Wu S X, Shen R N, Hong G B, et al. Development and validation of an artificial intelligence-based model for detecting urothelial carcinoma using urine cytology images: a multicentre, diagnostic study with prospective validation［J］. EClinicalMedicine, 2024, 71: 102566.
［23］Lebret T, Pignot G, Colombel M, et al. Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test［J］. BJU Int, 2022, 129(3): 356-363.
［24］Ma X Y, Hadjiiski L M, Wei J, et al. U-Net based deep learning bladder segmentation in CT urography［J］. Med Phys, 2019, 46(4): 1752-1765.
［25］O'Sullivan N J, Temperley H C, Corr A, et al. Current role of radiomics and radiogenomics in predicting oncological outcomes in bladder cancer［J］. Curr Urol, 2025, 19(1): 43-48.
［26］Xu X P, Zhang X, Tian Q, et al. Quantitative identification of nonmuscle-invasive and muscle-invasive bladder carcinomas: a multiparametric MRI radiomics analysis［J］. J Magn Reson Imaging, 2019, 49(5): 1489-1498.
［27］Woerl A C, Eckstein M, Geiger J, et al. Deep learning predicts molecular subtype of muscle-invasive bladder cancer from conventional histopathological slides［J］. Eur Urol, 2020, 78(2): 256-264.
［28］Loeffler C M L, Ortiz Bruechle N, Jung M, et al. Artificial intelligence-based detection of FGFR3 mutational status directly from routine histology in bladder cancer: a possible preselection for molecular testing?［J］. Eur Urol Focus, 2022, 8(2): 472-479.
［29］Sharma V, Fadel A, Tollefson M K, et al. Artificial intelligence-based assessment of preoperative body composition is associated with early complications after radical cystectomy［J］. J Urol, 2025, 213(2): 228-237.
［30］Suartz C V, Martinez L M, Cordeiro M D, et al. Artificial intelligence for predicting response to neoadjuvant chemotherapy for bladder cancer A comprehensive systematic review and meta-analysis［J］. Can Urol Assoc J, 2024, 18(9): E276-E284.
［31］Lotan Y, Krishna V, Abuzeid W M, et al. Predicting response to intravesical Bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12-center cohort［J］. J Urol, 2025, 213(2): 192-204.
［32］Manitz J, Gerhold-Ay A, Kieslich P, et al. Avelumab first-line maintenance in advanced urothelial carcinoma: complete screening for prognostic and predictive factors using machine learning in the JAVELIN bladder 100 phase 3 trial［J］. Cancer Med, 2024, 13(12): e7411.
［33］Xiong Y, Yao L P, Lin J L, et al. Artificial intelligence links CT images to pathologic features and survival outcomes of renal masses［J］. Nat Commun, 2025, 16(1): 1425.
［34］Silverman S G, Gan Y U, Mortele K J, et al. Renal masses in the adult patient: the role of percutaneous biopsy［J］. Radiology, 2006, 240(1): 6-22.
［35］Rasmussen R G, Xi Y, Sibley R C 3rd, et al. Association of clear cell likelihood score on MRI and growth kinetics of small solid renal masses on active surveillance［J］. AJR Am J Roentgenol, 2022, 218(1): 101-110.

［36］Etem T, Teke M. Enhanced deep learning based decision support system for kidney tumour detection［J］. BenchCouncil Trans Benchmarks Stand Eval, 2024, 4(2): 100174.

［37］Alzu'bi D, Abdullah M, Hmeidi I, et al. Kidney tumor detection and classification based on deep learning approaches: a new dataset in CT scans［J］. J Healthc Eng, 2022, 2022: 3861161.

［38］Kowalewski K F, Egen L, Fischetti C E, et al. Artificial intelligence for renal cancer: from imaging to histology and beyond［J］. Asian J Urol, 2022, 9(3): 243-252.
［39］Fenstermaker M, Tomlins S A, Singh K, et al. Development and validation of a deep-learning model to assist with renal cell carcinoma histopathologic interpretation［J］. Urology, 2020, 144: 152-157.
［40］Holdbrook D A, Singh M, Choudhury Y, et al. Automated renal cancer grading using nuclear pleomorphic patterns［J］. JCO Clin Cancer Inform, 2018, 2: 1-12.
［41］Singh N P, Bapi R S, Vinod P K. Machine learning models to predict the progression from early to late stages of papillary renal cell carcinoma［J］. Comput Biol Med, 2018, 100: 92-99.
［42］Shao L Z, Liang C, Yan Y, et al. An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer［J］. Nat Cancer, 2025, 6(10): 1621-1637.
［43］Kwong J C C, Al-Daqqaq Z, Chelliahpillai Y, et al. Development and international evaluation of an artificial intelligence-based model (PROGRxN-BCa) using the World Health Organization 2004/2022 grading system to predict progression risk and improve substratification for non-muscle-invasive bladder cancer［J/OL］. Eur Urol, (2025-10-07)［2025-10-09］. https://pubmed.ncbi.nlm.nih.gov/41062388/.
［44］Harmath C. AI in prostate cancer diagnosis with MRI: a friend not a foe［J］. Radiology, 2025, 314(3): e250525.

[1]	Liang Zheng, Liu Kuiliang, Ning Tingting, Li Peng, Zhang Shutian#, Wei Yongqiu. The application of artificial intelligence in the diagnosis and treatment of cholangiocarcinoma [J]. Journal of Capital Medical University, 2026, 47(1): 190-197.
[2]	Xie Lizhe , Yan Bin , Wang Lin. The application of artificial intelligence in stomatology [J]. Journal of Capital Medical University, 2025, 46(6): 968-976.
[3]	Lu Tian, Zhang Jiyi, Ma Wenkuo, Wang Yuji . From molecular building blocks to the materials: metal-organic frameworks facilitate drug discovery——2025 Nobel Prize in Chemistry [J]. Journal of Capital Medical University, 2025, 46(6): 1157-1165.
[4]	Wang Yongjie, Cui Libin, Yuan Xin, Lu Qian, Chen Xueming, Liu Liang. Efficacy analysis of artificial intelligence-assisted diagnosis for osteoporotic vertebral compression fracture [J]. Journal of Capital Medical University, 2025, 46(5): 777-783.
[5]	Pang Xingmei, Xie Zhiyun. Construction of a academic misconduct prevention system through “cognition-institution-technology” synergy-based under the perspective of artificial intelligence [J]. Journal of Capital Medical University, 2025, 46(4): 754-761.
[6]	Liu Honglei, Yang Yingliang, Li Ronghao, Zhu Congmin, Zhang Xu. Application of artificial intelligence in the study of cancer diagnosis and treatment research [J]. Journal of Capital Medical University, 2025, 46(3): 395-400.
[7]	Wang Yongjun, Liu Tao, Liu Ziyang, Xiong Yunyun, Jing Jing, Xie Xuewei, Li Zixiao. The applications of artificial intelligence in the field of cerebrovascular diseases [J]. Journal of Capital Medical University, 2025, 46(2): 177-183.
[8]	Li Qian, Zhu Hong, Ye Meng, Wu Yanzhe , Wu Li, Ma Weiwei. The correlation between phase angle and sarcopenia in middle-aged and elderly patients with type 2 diabetes mellitus [J]. Journal of Capital Medical University, 2025, 46(2): 340-347.
[9]	Zhang Wanwan, Dong Xiao, Yu Erlan, Ji Xunming, Wu Chuanjie. The application of artificial intelligence in the diagnosis and treatment of cerebrovascular disease [J]. Journal of Capital Medical University, 2025, 46(1): 6-10.
[10]	Wei Xingmei, Xue Shujin, Gao Zhencheng, Li Yongxin. The application of artificial intelligence in cochlear implantation [J]. Journal of Capital Medical University, 2024, 45(6): 931-937.
[11]	Pei Youjuan, Ruan Xiangyan, Ju Rui, Wang Yuejiao, Jiang Lingling, Ma Jun. The application of artificial intelligence in the reproductive endocrinology [J]. Journal of Capital Medical University, 2024, 45(4): 566-572.
[12]	Zhu Xiaohong, Zhang Yun, Liu Meiling, Cao Kai. Application value of GhostNet lightweight network in diagnosis of diabetic retinopathy [J]. Journal of Capital Medical University, 2024, 45(4): 678-687.
[13]	Zhao Jinming , Wang Xiangdong , Zhang Luo. The application of artificial intelligence in otolaryngology head and neck surgery [J]. Journal of Capital Medical University, 2024, 45(2): 175-180.
[14]	Luo Yi, Qin Qi, Wang Peihao, Guo Kangshun, Zhang Xinping, Cui Yong. Application and research progress of artificial intelligence combined with spectral diagnosis technology in the identification of lung cancer tissues [J]. Journal of Capital Medical University, 2023, 44(6): 1095-1102.
[15]	Zhang Yudong, Wei Houyi, Wang Runjin, Jiang Mingxin, Yang Kun, Wang Mingshuai, Wasilijiang Wahafu, Song Liming, Jin Mulan, Xing Nianzeng, Niu Yinong. Prognostic significance of the controlling nutritional status (CONUT) score in patients with bladder cancer treated with radical cystectomy and ileal conduit [J]. Journal of Capital Medical University, 2023, 44(3): 449-456.